Mepsevii

Active Ingredient(s): Vestronidase alfa-vjbk
FDA Approved: * November 15, 2017
Pharm Company: * ULTRAGENYX PHARM INC
Category: Genetic Disorders

Sly syndrome, also called mucopolysaccharidosis type VII (MPS-VII), is an autosomal recessive lysosomal storage disease caused by a deficiency of the enzyme β-glucuronidase. This enzyme is responsible for breaking down large sugar molecules called glycosaminoglycans (AKA GAGs, or mucopolysaccharides). The inability to break down GAGs leads to a buildup in many tissues and organs of the body. The severity of the disease can vary widely.[1] Contents 1 Signs and symptoms 2... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Mepsevii 2 mg/ml Intravenous Injection
NDC: 69794-001
Labeler:
Ultragenyx Pharmaceutical Inc.